Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations

Pavan Puligujja, Shantanu S. Balkundi, Lindsey M. Kendrick, Hannah M. Baldridge, James R. Hilaire, Aditya N. Bade, Prasanta K. Dash, Gang Zhang, Larisa Y Poluektova, Santhi Gorantla, Xin Ming Liu, Tianlei Ying, Yang Feng, Yanping Wang, Dimiter S. Dimitrov, JoEllyn M McMillan, Howard Eliot Gendelman

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte-macrophages could improve the drug's half-life and protein-binding capacities while facilitating cell and tissue depots. To this end, ART nanoparticles that target the folic acid (FA) receptor and permit cell-based drug depots were examined using pharmacokinetic and pharmacodynamic (PD) tests. FA receptor-targeted poloxamer 407 nanocrystals, containing ritonavir-boosted atazanavir (ATV/r), significantly increased drug bioavailability and PD by five and 100 times, respectively. Drug particles administered to human peripheral blood lymphocyte reconstituted NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice and infected with HIV-1ADA led to ATV/r drug concentrations that paralleled FA receptor beta staining in both the macrophage-rich parafollicular areas of spleen and lymph nodes. Drug levels were higher in these tissues than what could be achieved by either native drug or untargeted nanoART particles. The data also mirrored potent reductions in viral loads, tissue viral RNA and numbers of HIV-1p24+ cells in infected and treated animals. We conclude that FA-P407 coating of ART nanoparticles readily facilitates drug carriage and antiretroviral responses.

Original languageEnglish (US)
Pages (from-to)141-150
Number of pages10
JournalBiomaterials
Volume41
DOIs
StatePublished - Feb 1 2015

Fingerprint

Pharmacodynamics
Ritonavir
Folic Acid
Acids
Macrophages
Tissue
Pharmaceutical Preparations
Nanoparticles
Pharmacokinetics
Lymphocytes
RNA
Nanocrystals
Folate Receptor 2
Animals
Blood
HIV
Poloxamer
Coatings
Atazanavir Sulfate
Viral RNA

Keywords

  • Folic acid receptor
  • Human immunodeficiency virus type one
  • Long-acting nanoformulated antiretroviral therapy
  • Non-obese diabetic severe combined immunodeficient mice
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. / Puligujja, Pavan; Balkundi, Shantanu S.; Kendrick, Lindsey M.; Baldridge, Hannah M.; Hilaire, James R.; Bade, Aditya N.; Dash, Prasanta K.; Zhang, Gang; Poluektova, Larisa Y; Gorantla, Santhi; Liu, Xin Ming; Ying, Tianlei; Feng, Yang; Wang, Yanping; Dimitrov, Dimiter S.; McMillan, JoEllyn M; Gendelman, Howard Eliot.

In: Biomaterials, Vol. 41, 01.02.2015, p. 141-150.

Research output: Contribution to journalArticle

Puligujja, P, Balkundi, SS, Kendrick, LM, Baldridge, HM, Hilaire, JR, Bade, AN, Dash, PK, Zhang, G, Poluektova, LY, Gorantla, S, Liu, XM, Ying, T, Feng, Y, Wang, Y, Dimitrov, DS, McMillan, JM & Gendelman, HE 2015, 'Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations', Biomaterials, vol. 41, pp. 141-150. https://doi.org/10.1016/j.biomaterials.2014.11.012
Puligujja, Pavan ; Balkundi, Shantanu S. ; Kendrick, Lindsey M. ; Baldridge, Hannah M. ; Hilaire, James R. ; Bade, Aditya N. ; Dash, Prasanta K. ; Zhang, Gang ; Poluektova, Larisa Y ; Gorantla, Santhi ; Liu, Xin Ming ; Ying, Tianlei ; Feng, Yang ; Wang, Yanping ; Dimitrov, Dimiter S. ; McMillan, JoEllyn M ; Gendelman, Howard Eliot. / Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. In: Biomaterials. 2015 ; Vol. 41. pp. 141-150.
@article{ca0f3ce673224b719d4eea3b140bd59a,
title = "Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations",
abstract = "Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte-macrophages could improve the drug's half-life and protein-binding capacities while facilitating cell and tissue depots. To this end, ART nanoparticles that target the folic acid (FA) receptor and permit cell-based drug depots were examined using pharmacokinetic and pharmacodynamic (PD) tests. FA receptor-targeted poloxamer 407 nanocrystals, containing ritonavir-boosted atazanavir (ATV/r), significantly increased drug bioavailability and PD by five and 100 times, respectively. Drug particles administered to human peripheral blood lymphocyte reconstituted NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice and infected with HIV-1ADA led to ATV/r drug concentrations that paralleled FA receptor beta staining in both the macrophage-rich parafollicular areas of spleen and lymph nodes. Drug levels were higher in these tissues than what could be achieved by either native drug or untargeted nanoART particles. The data also mirrored potent reductions in viral loads, tissue viral RNA and numbers of HIV-1p24+ cells in infected and treated animals. We conclude that FA-P407 coating of ART nanoparticles readily facilitates drug carriage and antiretroviral responses.",
keywords = "Folic acid receptor, Human immunodeficiency virus type one, Long-acting nanoformulated antiretroviral therapy, Non-obese diabetic severe combined immunodeficient mice, Pharmacodynamics, Pharmacokinetics",
author = "Pavan Puligujja and Balkundi, {Shantanu S.} and Kendrick, {Lindsey M.} and Baldridge, {Hannah M.} and Hilaire, {James R.} and Bade, {Aditya N.} and Dash, {Prasanta K.} and Gang Zhang and Poluektova, {Larisa Y} and Santhi Gorantla and Liu, {Xin Ming} and Tianlei Ying and Yang Feng and Yanping Wang and Dimitrov, {Dimiter S.} and McMillan, {JoEllyn M} and Gendelman, {Howard Eliot}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2014.11.012",
language = "English (US)",
volume = "41",
pages = "141--150",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations

AU - Puligujja, Pavan

AU - Balkundi, Shantanu S.

AU - Kendrick, Lindsey M.

AU - Baldridge, Hannah M.

AU - Hilaire, James R.

AU - Bade, Aditya N.

AU - Dash, Prasanta K.

AU - Zhang, Gang

AU - Poluektova, Larisa Y

AU - Gorantla, Santhi

AU - Liu, Xin Ming

AU - Ying, Tianlei

AU - Feng, Yang

AU - Wang, Yanping

AU - Dimitrov, Dimiter S.

AU - McMillan, JoEllyn M

AU - Gendelman, Howard Eliot

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte-macrophages could improve the drug's half-life and protein-binding capacities while facilitating cell and tissue depots. To this end, ART nanoparticles that target the folic acid (FA) receptor and permit cell-based drug depots were examined using pharmacokinetic and pharmacodynamic (PD) tests. FA receptor-targeted poloxamer 407 nanocrystals, containing ritonavir-boosted atazanavir (ATV/r), significantly increased drug bioavailability and PD by five and 100 times, respectively. Drug particles administered to human peripheral blood lymphocyte reconstituted NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice and infected with HIV-1ADA led to ATV/r drug concentrations that paralleled FA receptor beta staining in both the macrophage-rich parafollicular areas of spleen and lymph nodes. Drug levels were higher in these tissues than what could be achieved by either native drug or untargeted nanoART particles. The data also mirrored potent reductions in viral loads, tissue viral RNA and numbers of HIV-1p24+ cells in infected and treated animals. We conclude that FA-P407 coating of ART nanoparticles readily facilitates drug carriage and antiretroviral responses.

AB - Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte-macrophages could improve the drug's half-life and protein-binding capacities while facilitating cell and tissue depots. To this end, ART nanoparticles that target the folic acid (FA) receptor and permit cell-based drug depots were examined using pharmacokinetic and pharmacodynamic (PD) tests. FA receptor-targeted poloxamer 407 nanocrystals, containing ritonavir-boosted atazanavir (ATV/r), significantly increased drug bioavailability and PD by five and 100 times, respectively. Drug particles administered to human peripheral blood lymphocyte reconstituted NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice and infected with HIV-1ADA led to ATV/r drug concentrations that paralleled FA receptor beta staining in both the macrophage-rich parafollicular areas of spleen and lymph nodes. Drug levels were higher in these tissues than what could be achieved by either native drug or untargeted nanoART particles. The data also mirrored potent reductions in viral loads, tissue viral RNA and numbers of HIV-1p24+ cells in infected and treated animals. We conclude that FA-P407 coating of ART nanoparticles readily facilitates drug carriage and antiretroviral responses.

KW - Folic acid receptor

KW - Human immunodeficiency virus type one

KW - Long-acting nanoformulated antiretroviral therapy

KW - Non-obese diabetic severe combined immunodeficient mice

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84916940064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916940064&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2014.11.012

DO - 10.1016/j.biomaterials.2014.11.012

M3 - Article

C2 - 25522973

AN - SCOPUS:84916940064

VL - 41

SP - 141

EP - 150

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -